EA200971093A1 - Терапевтические композиции и их применение - Google Patents

Терапевтические композиции и их применение

Info

Publication number
EA200971093A1
EA200971093A1 EA200971093A EA200971093A EA200971093A1 EA 200971093 A1 EA200971093 A1 EA 200971093A1 EA 200971093 A EA200971093 A EA 200971093A EA 200971093 A EA200971093 A EA 200971093A EA 200971093 A1 EA200971093 A1 EA 200971093A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutically acceptable
acceptable salt
application
therapeutic compositions
compositions
Prior art date
Application number
EA200971093A
Other languages
English (en)
Inventor
Брайан П. Кирни
Анита А. Матиас
Сринивасан Раманатан
Original Assignee
Джилид Сайэнс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джилид Сайэнс, Инк. filed Critical Джилид Сайэнс, Инк.
Publication of EA200971093A1 publication Critical patent/EA200971093A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение включает способы, композиции и наборы, подходящие для лечения вирусной инфекции путем введения 6-(3-хлор-2-фторбензил)-1-[(2S)-1-гидрокси-3-метилбутан-2-ил]-7-метокси-4-оксо-1,4-дигидрохинолин-3-карбоновой кислоты или фармацевтически приемлемой соли указанного соединения совместно с атазанавиром (atazanavir) или его фармацевтически приемлемой солью и, возможно, с соединением, ингибирующим цитохром Р-450, или фармацевтически приемлемой солью указанного соединения.
EA200971093A 2007-06-29 2008-06-26 Терапевтические композиции и их применение EA200971093A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94730607P 2007-06-29 2007-06-29
US4092008P 2008-03-31 2008-03-31
PCT/US2008/068339 WO2009006199A1 (en) 2007-06-29 2008-06-26 Therapeutic compositions and the use thereof

Publications (1)

Publication Number Publication Date
EA200971093A1 true EA200971093A1 (ru) 2010-08-30

Family

ID=39831893

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200971093A EA200971093A1 (ru) 2007-06-29 2008-06-26 Терапевтические композиции и их применение

Country Status (19)

Country Link
US (4) US20100331331A1 (ru)
EP (1) EP2167088A1 (ru)
JP (3) JP5547066B2 (ru)
KR (1) KR20100040892A (ru)
CN (2) CN101686972B (ru)
AP (1) AP2965A (ru)
AR (1) AR067183A1 (ru)
AU (1) AU2008270630B2 (ru)
BR (1) BRPI0813000A2 (ru)
CA (1) CA2692101A1 (ru)
CO (1) CO6251237A2 (ru)
EA (1) EA200971093A1 (ru)
EC (1) ECSP109897A (ru)
IL (1) IL202744A0 (ru)
MX (1) MX2009013829A (ru)
NZ (1) NZ582086A (ru)
SG (1) SG182229A1 (ru)
TW (1) TW200914011A (ru)
WO (1) WO2009006199A1 (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201201496A1 (ru) * 2005-12-30 2013-07-30 Джилид Сайэнс, Инк. Способ ингибирования интегразы вич, способ улучшения фармакокинетики 6-(3-хлор-2-фторбензил)-1-[(2s)-1-гидрокси-3-метилбутан-2-ил]-7-метокси-4-оксо-1,4-дигидрохинолин-3-карбоновой кислоты (варианты), набор, фармацевтическая композиция (варианты) и антиретровирусный агент (варианты)
EA020489B1 (ru) 2006-07-07 2014-11-28 Джилид Сайэнс, Инк. Модуляторы фармакокинетических свойств лекарственных средств
WO2008033836A2 (en) 2006-09-12 2008-03-20 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
SG183059A1 (en) * 2007-02-23 2012-08-30 Gilead Sciences Inc Modulators of pharmacokinetic properties of therapeutics
NZ582089A (en) * 2007-06-29 2013-01-25 Gilead Sciences Inc Antiviral Combination of elvitegravir, lopinavir and optionally ritonavir
AR067183A1 (es) * 2007-06-29 2009-09-30 Gilead Sciences Inc Composiciones terapeuticas y metodos, usos y equipos
AR068403A1 (es) * 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
PL2296633T3 (pl) 2008-05-02 2016-03-31 Gilead Sciences Inc Zastosowanie cząsteczek stałych nośników dla udoskonalenia przetwarzalności środka farmaceutycznego
WO2011127244A2 (en) * 2010-04-09 2011-10-13 Bristol-Myers Squibb Company ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED pH EFFECT
WO2012088178A1 (en) * 2010-12-21 2012-06-28 Gilead Sciences, Inc. Inhibitors of cytochrome p450 (cyp3a4)
CN104185420B (zh) 2011-11-30 2017-06-09 埃默里大学 用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂
EP2880017B1 (en) 2012-08-03 2016-10-05 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
DK3067358T3 (da) 2012-12-21 2019-11-04 Gilead Sciences Inc Polycykliske carbamoylpyridon-forbindelser og deres farmaceutiske anvendelse
PT3019503T (pt) 2013-07-12 2017-11-27 Gilead Sciences Inc Compostos carbamoílpiridona- policíclicos e seu uso para o tratamento de infecções por hiv
NO2865735T3 (ru) 2013-07-12 2018-07-21
US9463194B2 (en) 2014-02-05 2016-10-11 Gilead Sciences, Inc. Methods of treating patients co-infected with HIV and tuberculosis
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
NO2717902T3 (ru) 2014-06-20 2018-06-23
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
KR20170123308A (ko) 2014-12-26 2017-11-07 에모리 유니버시티 Ｎ4-하이드록시시티딘, 이와 관련된 유도체 및 이의 항 바이러스적 용도
KR20190057158A (ko) 2015-04-02 2019-05-27 길리애드 사이언시즈, 인코포레이티드 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도
BR122022008466B1 (pt) 2017-12-07 2023-12-05 Emory University Uso de um composto

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552558A (en) * 1989-05-23 1996-09-03 Abbott Laboratories Retroviral protease inhibiting compounds
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5849911A (en) * 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
US6087383A (en) * 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
US6544540B2 (en) * 1998-07-29 2003-04-08 Syngenta Limited Base-triggered release microcapsules
SK2662004A3 (sk) * 2002-11-20 2005-06-02 Japan Tobacco, Inc. Zlúčenina s obsahom 4-oxochinolínu a jej použitie ako inhibítora integráz
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
EP2332538A1 (en) * 2004-05-21 2011-06-15 Japan Tobacco, Inc. Combinations comprising a 4-isoquinolone derivative and anti-HIV agents
US20060058286A1 (en) * 2004-09-16 2006-03-16 Mark Krystal Methods of treating HIV infection
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
EA201201496A1 (ru) * 2005-12-30 2013-07-30 Джилид Сайэнс, Инк. Способ ингибирования интегразы вич, способ улучшения фармакокинетики 6-(3-хлор-2-фторбензил)-1-[(2s)-1-гидрокси-3-метилбутан-2-ил]-7-метокси-4-оксо-1,4-дигидрохинолин-3-карбоновой кислоты (варианты), набор, фармацевтическая композиция (варианты) и антиретровирусный агент (варианты)
EA020489B1 (ru) * 2006-07-07 2014-11-28 Джилид Сайэнс, Инк. Модуляторы фармакокинетических свойств лекарственных средств
WO2008033836A2 (en) * 2006-09-12 2008-03-20 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
AR067183A1 (es) * 2007-06-29 2009-09-30 Gilead Sciences Inc Composiciones terapeuticas y metodos, usos y equipos
NZ582089A (en) * 2007-06-29 2013-01-25 Gilead Sciences Inc Antiviral Combination of elvitegravir, lopinavir and optionally ritonavir
AR068403A1 (es) * 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
PL2296633T3 (pl) * 2008-05-02 2016-03-31 Gilead Sciences Inc Zastosowanie cząsteczek stałych nośników dla udoskonalenia przetwarzalności środka farmaceutycznego
US20110000941A1 (en) * 2009-07-06 2011-01-06 Volk J Patrick Apparatus and System for Carrying a Digital Media Player

Also Published As

Publication number Publication date
IL202744A0 (en) 2010-06-30
CN101686972A (zh) 2010-03-31
JP5769763B2 (ja) 2015-08-26
AU2008270630B2 (en) 2014-01-16
US20140343063A1 (en) 2014-11-20
JP2015143278A (ja) 2015-08-06
ECSP109897A (es) 2010-03-31
MX2009013829A (es) 2010-03-10
BRPI0813000A2 (pt) 2014-12-23
US20100331331A1 (en) 2010-12-30
CN101686972B (zh) 2013-08-14
AU2008270630A1 (en) 2009-01-08
AR067183A1 (es) 2009-09-30
AP2009005074A0 (en) 2009-12-31
EP2167088A1 (en) 2010-03-31
US20090093467A1 (en) 2009-04-09
JP2013199495A (ja) 2013-10-03
JP5547066B2 (ja) 2014-07-09
TW200914011A (en) 2009-04-01
AP2965A (en) 2014-09-30
US20170136001A1 (en) 2017-05-18
JP2010532372A (ja) 2010-10-07
SG182229A1 (en) 2012-07-30
KR20100040892A (ko) 2010-04-21
CN103480000A (zh) 2014-01-01
NZ582086A (en) 2012-07-27
CO6251237A2 (es) 2011-02-21
CA2692101A1 (en) 2009-01-08
WO2009006199A1 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
EA200971093A1 (ru) Терапевтические композиции и их применение
EA200971096A1 (ru) Терапевтические композиции и их применение
EA201291301A1 (ru) Производные 2-хинолинилуксусной кислоты в качестве противовирусных соединений против вич
PH12015502056A1 (en) Benzothiazole compounds and their pharmaceutical use
BR112012003578A8 (pt) Composto, sal farmaceuticamente aceitável, sal de sulfato, composição farmacêutica, método para tratar uma infecção viral, e, uso de um composto ou sal
BR112017022544A2 (pt) ?composto, composição, e, método para tratamento de infecção por hiv?.
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
WO2014134566A3 (en) Amide compounds for the treatment of hiv
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
EA201270247A1 (ru) Способы применения с-мет-модуляторов
EA201390428A1 (ru) Композиции и способы лечения легочной гипертензии
EA200901241A1 (ru) Соединения для лечения гепатита с
BR112012026767A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal
EA201290053A1 (ru) Ингибиторы вирусов flaviviridae
EA201170441A1 (ru) Терапевтические противовирусные пептиды
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
EA201270275A1 (ru) Кристаллическое соединение пиридазина
EA201000895A1 (ru) Композиции и способы для лечения лизосомных болезней
EA201190293A1 (ru) Пролекарства триптолида
EA200700550A1 (ru) Производные алкилидентетрагидронафталина, способ их получения и их применение в качестве противовоспалительных средств
EA201001566A1 (ru) Новый класс спиропиперидинов для лечения нейродегенеративных заболеваний
WO2007076091A3 (en) Treatment of viral infections using a tissue factor inhibitor
WO2008024423A3 (en) 4-thio substituted quinoline and naphthyridine compounds
UA103880C2 (ru) Профилактика или терапевтическое лечение инфекции, вызванной вирусом иммунодефицита человека